EU orders additional COVID-19 vaccine doses
Pfizer Inc. and BioNTech SE have signed an agreement with the European Commission (EC) to supply an additional 200 million doses of BNT162b2 to the EU.
Novel strategy targets chronic liver diseases
A resesarch team headed by HepaRegeneriX Board Member Lars Zender has presented a new approach to treat hepatocellular carcinoma (HCC) by disturbing the lipid metabolism of tumour cells.
Cellectis and Cytovia in US$760m licence deal
Cell therapy specialist Cytovia Therapeutics Inc and genome editing expert Cellectis SAS partner to develop iPSC-derived natural killer (NK) cell-based cancer therapies.
Cellink AB acquires Ginolis Oy for 70m
Cellink AB will take over all shares of Ginolis Oy, a Finnish company focusing on diagnostics automation and advanced robotics solutions for medical and diagnostic industries.
Rentschler Biopharma launches gene therapy subsidiary
CDMO Rentschler Biopharma will establish a Center of Excellence for cell and gene therapy through a new UK subsidiary Rentschler ATMP Ltd.
InteRNA Technologies secures 18.5m in Series B financing
MicroRNA-based therapeutics developer InteRNA Technologies has closed an extended Series B round totaling 18.5m led by AurorA Science, an Italian biotech investment company.
German Health Ministry to invest 6.2bn in vaccines
The German Health Ministry has requested 6.2bn from the Federal Ministry of Finance to purchase up to 635 million additional doses of COVID-19 vaccines.
V-Bio Ventures launches second fund at 78m
V-Bio Ventures has announced the first closing of its V-Bio Fund 2 at 78m. The fund is focussed on investments into early stage life sciences companies in Belgium and the EU.
·
Abingworth raises US-$465m for new life sciences fund
The transatlantic Abingworth Bioventures 8 Fund has been closed at $464m to invest in US, UK and European life science companies.
Two companies aim for 2nd-gen COVID vaccines
As rapidly spreading mutants of SARS-CoV-2 are emerging, two Tuebingen-based vaccine developers will develop multivalent COVID-19 vaccines.